Gapping up
News:
- MOLN +11.3% (to collaborate with Novartis (NVS) to develop DARPin-conjugated radioligand therapeutic candidates for oncology)
- IMTX +9.9% (Immatics N.V. and Bristol Myers Squibb (BMY) enter into global exclusive license for Immatics' TCR Bispecific Program IMA401)
- ATRA +9.3% (Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel at the 63rd American Society of Hematology (ASH) Annual Meeting)
- SNSE +6.9% (to be added to the NASDAQ Biotech Index)
- NEOG +6% (to combine 3M's (MMM) Food Safety business with its existing operations)
- AA +4.2% (to join S&P MidCap 400; also announces closure of aluminum smelting capacity at Wenatchee)
- LAZR +3.7% (announced its authorization and intent to purchase $250 mln or more of its Class A common stock which is anticipated to commence today after market open)
- EQT +3.6% (approves $1 bln share repurchase program also to reinstate its dividend)
- NGD +3.5% (to sell Blackwater Project gold stream for upfront cash consideration US$300 mln)
- FATE +3.1% (showcases positive interim phase 1 Data for FT596)
- AFG +3.1% (declares special cash dividend of $2.00/sh)
- TGTX +2.5% (FDA has accepted the Biologics License Application for ublituximab)
- ALSN +1.7% (selected by Israeli Ministry of Defense for infantry fighting vehicle)
- KMPH +1.7% (to be added to the NASDAQ Biotech Index)
- ELY +1.7% (approves $50 mln share repurchase program)
- SV +1.5% (NuScale Power announces plans to go public via merger with Spring Valley Acquisition Corp)
- PGEN +1.4% (positive interim phase 1 data for PRGN-3006 UltraCAR-T)
- LDOS +1.3% (awarded contract by U.S. Air Force worth an estimated $82 mln)
- TALS +1.3% (presented a new analysis of HLA mismatching between donors and recipients participating in the Company's Phase 2 trial in living donor kidney transplant)
- GIIX +1.2% (FOOTPRINT to be publicly listed on NASDAQ through combination with Gores Holdings VIII)
Analyst comments:
- BYND +4.3% (upgraded to Neutral from Underweight at Piper Sandler)
- MODN +2.3% (upgraded to Overweight from Neutral at JP Morgan)
- CPRI +1.6% (upgraded to Buy from Neutral at Goldman)
- NOV +1.5% (upgraded to Overweight from Neutral at JP Morgan)
- CRWD +1.4% (upgraded to Overweight from Neutral at JP Morgan)
- AVLR +0.9% (upgraded to Overweight from Neutral at JP Morgan)
- AAPL +0.8% (upgraded to Buy from Neutral at BofA Securities)